about
DNA mismatch repair protein Msh6 is required for optimal levels of ultraviolet-B-induced apoptosis in primary mouse fibroblastsQuantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis.The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.Posttransplant Lymphoproliferative Disorder After Clinical Islet Transplantation: Report of the First Two Cases.The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single Center Experience.Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model.Epstein-Barr virus associated smooth muscle tumors in solid organ transplant recipients: Incidence over 31 years at a single institution and review of the literatureIncremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid LeukemiaAutologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real worldFailure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorderIND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemiaThe Adverse Consequences of Initial Watchful Waiting for Patients With Follicular LymphomaCharacteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy
P50
Q28512103-D6C1E0A8-8663-4F0B-AF00-D7A3EEBE7DBEQ40088647-036C827E-BF13-4141-8599-468B30715564Q40827250-35264038-37D8-4902-AD68-1132465E7247Q47799831-5D4AC5AE-1318-4835-A758-592EE573A036Q51747060-C06B2B0C-4217-4D66-B1D0-7BFEB099EE5CQ53150176-CBD60184-BBB8-4469-9980-26754BBDCA51Q55456143-2981D630-3353-4E39-B4E7-27F851600DC0Q57292690-8CB67CDC-E2E3-4011-82B5-C4DF375807DBQ89253986-2C0F75C7-23FD-4F50-80AD-F130A46D195FQ89389879-0DDF5727-A923-4738-A032-87C3B7BC0D75Q89753349-D31D937D-8852-42B0-AA15-99102ECCEAACQ90184426-F86B6447-FFD5-4C58-B256-9E6ECD628A22Q91651093-82108CD2-5D50-4A02-81EB-50416B9E03B3Q96233884-AD180121-31BE-43E3-AC2C-F0B1FA866715
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Anthea C Peters
@en
Anthea C Peters
@nl
type
label
Anthea C Peters
@en
Anthea C Peters
@nl
prefLabel
Anthea C Peters
@en
Anthea C Peters
@nl
P31
P496
0000-0002-2570-339X